A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004
2007

Trends in Antibiotic Resistance in ICU Pathogens

Sample size: 74494 publication Evidence: moderate

Author Information

Author(s): Eagye Kathryn J, Nicolau David P, Lockhart Shawn R, Quinn John P, Doern Gary V, Gallagher Gale, Abramson Murray A

Primary Institution: Center for Anti-Infective Research and Development, Hartford Hospital

Hypothesis

Have MICs among major pathogens in the ICU increased enough to significantly impact their ability to achieve bactericidal effect?

Conclusion

Increasing antimicrobial resistance among ICU pathogens in the US has led to a decline in drug effectiveness, particularly for P. aeruginosa and Acinetobacter spp.

Supporting Evidence

  • Imipenem showed a trend toward slightly improved bactericidal target attainment.
  • Cefepime and piperacillin-tazobactam showed declines in effectiveness over time.
  • Ceftriaxone had low predicted response rates across all periods.

Takeaway

Doctors need to give higher doses of certain antibiotics to help them work better against germs that are becoming stronger and harder to kill.

Methodology

Monte Carlo simulations were used to estimate the probability of achieving bactericidal effects of four antibiotics against Gram-negative bacilli from ICU patients.

Limitations

The study only included data from ICU patients in the US and may not be generalizable to other settings.

Participant Demographics

Patients with various infections in intensive care units in the United States.

Statistical Information

P-Value

<0.01

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1476-0711-6-11

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication